Business Context and Reporting Period
This Form 8-K Current Report is filed by AgeX Therapeutics, Inc. (not Serina Therapeutics, Inc.) for the reporting period ending June 6, 2022. The company is an emerging growth company incorporated in Delaware, with its principal executive offices in Alameda, California. The filing details a new debt draw and the issuance of unregistered equity securities.
Key Financial Metrics and Obligations
- Debt Draw: AgeX borrowed an additional $1,000,000 under a Secured Convertible Promissory Note with Juvenescence Limited.
- Total Borrowed: The cumulative amount borrowed under the line of credit is now $10,160,000.
- Remaining Capacity: Up to $3,000,000 remains available for future draws, subject to lender discretion and a $1 million limit per single draw.
- Repayment Date: The outstanding principal balance is due on February 14, 2024.
- Cost of Capital: Instead of accrued interest, the company pays an Origination Fee of 4% on each draw and an additional 4% on the total drawn amount after the 12-month draw period.
- Equity Issuance: In connection with the draw, AgeX issued warrants to purchase 703,234 shares of common stock at an exercise price of $0.711 per share.
Material Changes Versus Prior Period
The filing reports a material increase in the company's direct financial obligations. The total principal balance under the Secured Note increased from $9.16 million to $10.16 million following the June 6, 2022 draw. Additionally, the company's capital structure was altered by the issuance of new unregistered warrants to the lender.
Guidance, Risks, and Contingencies
- Forward-Looking Statements: The filing includes standard disclaimers regarding forward-looking statements, noting that actual results may differ materially due to risk factors outlined in periodic reports.
- Events of Default: The Secured Note contains extensive default provisions, including failure to pay principal or fees, breach of covenants, cross-defaults on other indebtedness exceeding $100,000, insolvency, bankruptcy proceedings, loss of material assets, or material adverse changes in financial condition.
- Acceleration: Upon an Event of Default, the entire outstanding principal and accrued fees may become immediately due and payable.
- Liquidity Constraints: Future draws are subject to the lender's discretion and a cap of $1 million per transaction.
Investor Verification Checklist
- Verify the total outstanding debt balance of $10.16 million and the remaining $3 million credit facility availability.
- Confirm the total cost of the debt, including the 4% per-draw fee and the additional 4% fee on total funds drawn post-draw period.
- Review the terms of the 703,234 warrants issued, specifically the $0.711 exercise price and listing approval status on NYSE American.
- Assess the company's ability to meet the February 14, 2024, repayment date given its current cash flow and burn rate.
- Examine the "Risk Factors" section of the company's most recent 10-K or 10-Q for details on the specific risks associated with the Secured Note and the lender's discretion.